Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Katherine A. High was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Summary

• Director Katherine A. High received a grant of 13,000 stock options for CRISPR Therapeutics AG common shares.
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are subject to a one-year vesting schedule, with 12 equal monthly installments beginning June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market volatility may impact the value of the granted options.
• Vesting is contingent upon continued service to the company.

Future Outlook

The options vest in 12 equal monthly installments over one year, concluding on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level scientific and clinical expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of monthly vesting over one year is a common retention mechanism for board members in the life sciences industry.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Stock Options, Biotech, Gene Editing